Callan Capital LLC buys 178 shares of Zoetis Inc. (NYSE:ZTS)

Callan Capital LLC grew its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 7.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,688 shares of the company’s stock after buying an additional 178 shares during the period. Callan Capital LLC’s holdings in Zoetis were worth $466,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also bought and sold shares of ZTS. Aveo Capital Partners LLC acquired a new position in Zoetis in the 4th quarter valued at approximately $225,000. Gryphon Financial Partners LLC boosted its holdings in shares of Zoetis by 11.8% in the fourth quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after purchasing an additional 322 shares in the last quarter. Jump Financial LLC acquired a new position in Zoetis in the fourth quarter valued at about $339,000. TrinityPoint Wealth LLC boosted its holdings in Zoetis by 0.3% during the 4th quarter. TrinityPoint Wealth LLC now owns 22,319 shares of the company’s stock worth $4,405,000 after acquiring an additional 73 shares during the period. Finally, Franklin Resources Inc. raised its stake in Zoetis by 8.9% in the 4th quarter. Franklin Resources Inc. now owns 161,489 shares of the company’s stock worth $31,873,000 after buying an additional 13,236 shares during the last quarter. 92.80% of shares are held by hedge funds and other institutional investors.

Zoetis stock performance

Shares of Zoetis stock opened at $192.73 on Friday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a market cap of $87.94 billion, a P/E ratio of 37.13, a P/E/G ratio of 2.98 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09, and a debt-to-equity ratio of 1.32. The firm has a 50-day moving average of $184.70 and a 200-day moving average of $174.47.

Zoetis (NYSE:ZTS – Get Free Report ) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company’s revenue increased by 8.3% year-on-year. In the same quarter last year, the company posted earnings of $1.41 per share. Sell-side analysts expect that Zoetis Inc. will record 5.84 EPS for the current year.

Changes in Analyst Ratings

Several research analysts recently weighed in on ZTS shares. Stifel Nicolaus upped their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. BTIG Research boosted their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $220.38, according to data from MarketBeat.com.

Read the latest stock report on ZTS

About Zoetis

(Free Report)

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products and services in the United States and internationally. The company mainly markets products by species, including livestock such as cattle, swine, poultry, fish and sheep and others; and pets including dogs, cats and horses.

Featured stories

Get news and reviews for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.